TY - JOUR
T1 - Itraconazole treatment of phaeohyphomycosis
AU - Sharkey, Patricia Kay
AU - Graybill, John R.
AU - Rinaldi, Michael G.
AU - Stevens, David A.
AU - Tucker, Richard M.
AU - Peterie, Jerry D.
AU - Hoeprich, Paul D.
AU - Greer, Donald L.
AU - Frenkel, Lisa
AU - Counts, George W.
AU - Goodrich, James
AU - Zellner, Stephen
AU - Bradsher, Robert W.
AU - van der Horst, Charles M.
AU - Israel, Karen
AU - Pankey, George A.
AU - Barranco, Charles P.
PY - 1990
Y1 - 1990
N2 - Nineteen patients with phaeohyphomycosis were treated with itraconazole. Of these, 17 were assessable for clinical outcome. Of these, two had received no prior therapy, five had failed amphotericin B therapy, four had failed ketoconazole or miconazole therapy, and five had failed both amphotericin B and azole therapy. One patient had received only prior surgical intervention. Fungi of seven different genera caused disease of the skin in nine patients, soft tissue in nine, sinuses in eight, bone in five, joints in two, and lungs in two. Itraconazole was given in dosages ranging from 50 to 600 mg/day for 1 to 48 months. Clinical improvement or remission occurred in nine patients. Two patients have had stabilization of disease. Six patients failed treatment, one had a relapse after initially successful treatment. Itraconazole appears to be highly effective in some patients with phaeohyphomycosis, including patients refractory to other antifungal agents.
AB - Nineteen patients with phaeohyphomycosis were treated with itraconazole. Of these, 17 were assessable for clinical outcome. Of these, two had received no prior therapy, five had failed amphotericin B therapy, four had failed ketoconazole or miconazole therapy, and five had failed both amphotericin B and azole therapy. One patient had received only prior surgical intervention. Fungi of seven different genera caused disease of the skin in nine patients, soft tissue in nine, sinuses in eight, bone in five, joints in two, and lungs in two. Itraconazole was given in dosages ranging from 50 to 600 mg/day for 1 to 48 months. Clinical improvement or remission occurred in nine patients. Two patients have had stabilization of disease. Six patients failed treatment, one had a relapse after initially successful treatment. Itraconazole appears to be highly effective in some patients with phaeohyphomycosis, including patients refractory to other antifungal agents.
UR - http://www.scopus.com/inward/record.url?scp=0025130518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025130518&partnerID=8YFLogxK
U2 - 10.1016/0190-9622(90)70259-K
DO - 10.1016/0190-9622(90)70259-K
M3 - Article
C2 - 2170477
AN - SCOPUS:0025130518
VL - 23
SP - 577
EP - 586
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 3
ER -